Moderna and Merck say their mRNA melanoma vaccine cut death and recurrence by 42%
Moderna and Merck report that their personalised mRNA vaccine, added to standard treatment, cut the risk of death or recurrence by 42% in a Phase 3 trial of 1,137 patients with…
1 post ·